Down 30%: What Caused Idenix's Crash?
Jun 21st 2013 8:30PM
Updated Jun 21st 2013 8:32PM
Idenix Pharmaceuticals received more bad news today after reporting that the FDA will require more preclinical data before it can proceed with clinical trials for its experimental hepatitis C drug IDX20963. In the following video, health-care analyst Max Macaluso discusses what this news means in the context of Idenix's previous drug development problems.
Taking a break from the volatile biotech sector? Looking for ways to diversify into dividend-paying stocks? The Motley Fool's special report "Secure Your Future With 9 Rock-Solid Dividend Stocks" is a great way to kick-start your search. Just click here to get your free copy today.
The article Down 30%: What Caused Idenix's Crash? originally appeared on Fool.com.Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.